Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss management Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived drug development. Through the Filament acquisition, the Company also holds Filament's interest in Magdalena Biosciences, Inc. ("Magdalena"), a US based joint venture formed by Filament and Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar"). The Company is pleased to report that Magdalena has announced positive results of a preclinical study demonstrating that a novel extract derived from the leaves of the coca plant prevented weight gain in mice placed on a high fat diet, without reducing food intake or increasing physical activity. The coca leaf extract under evaluation is Magdalena's prescription drug candidate for post-GLP-1 weight loss management, intended for development under the U.S. Food and Drug Administration's Botanical Guidance. It is common for people to regain weight after stopping GLP-1 medications, as these drugs help reduce appetite and increase feelings of fullness while they are being taken. When treatment is discontinued, those effects diminish, and the body's mechanisms that regulate hunger and body weight may promote weight gain. Magdalena's thesis is that the coca leaf extract under evaluation may have the potential to serve as a weight maintenance therapy following cessation of GLP-1 therapy, addressing a significant unmet need for safe, long term weight management solutions. The 20 day preclinical study was conducted in Alberta, Canada, in collaboration with the Borgland Lab at the University of Calgary, where Stephanie Borgland, PhD, served as Principal Investigator. The coca leaf used in the research and development program was provided to Magdalena by Empresa Nacional de La Coca (ENACO), a Peruvian state company dedicated to the commercialization of the coca leaf and its derivatives, under an Internationally Recognized Certificate of Compliance (IRCC) consistent with the Nagoya Protocol requirements of Peru. Indigenous peoples and healers in the Andean region have utilized coca for centuries to manage hunger and fatigue. "This is an encouraging early result from Magdalena Biosciences and a clear example of the broader value created through our acquisition of Filament," said Todd Shapiro, Chief Executive Officer and Director of both Red Light and Filament. "Beyond Filament's leadership in standardized, naturally derived psilocybin, the acquisition gives Red Light an interest in a botanical drug development program addressing a large and growing unmet need in weight management. We look forward to supporting Magdalena and our partners at Jaguar as this candidate advances under the FDA's Botanical Guidance." Filament is Red Light's wholly owned subsidiary and a partner, alongside Jaguar, in the Magdalena Biosciences joint venture. The Company believes that the development of standardized, naturally derived botanical medicines, advanced under quality controlled and regulatory conscious frameworks, can offer new mechanisms of action while being potentially safer than chemically synthesized small molecule drugs. About Red Light Holland Red Light is an Ontario based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and R&D initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, the Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws. About Filament Health Filament Health is a clinical stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first ever natural psychedelic drug candidates. About Magdalena Biosciences Magdalena Biosciences, Inc. is a US based joint venture formed by Jaguar Health, Inc. and Filament Health Corp. in 2023 to develop novel, natural prescription medicines derived from plants for weight gain prevention and mental health indications. Magdale